Stock Research for ACRX

ACRX
Current Price

$2.0500


Latest Update: 2018-01-19 16:00:00

High
$ 2.0500
Low
$ 2.0000
Close
$ 2.0500
Volume
21735
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

ACRX Stock Chart & Research Data

The ACRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ACRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ACRX Due diligence Resources & Stock Charts

The ACRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ACRX Detailed Price Forecast - CNN Money CNN View ACRX Detailed Summary - Google Finance
Yahoo View ACRX Detailed Summary - Yahoo! Finance Zacks View ACRX Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ACRX Trends & Analysis - Trade-Ideas Barrons View ACRX Major Holders - Barrons
NASDAQ View ACRX Call Transcripts - NASDAQ Seeking View ACRX Breaking News & Analysis - Seeking Alpha
Spotlight View ACRX Annual Report - CompanySpotlight.com OTC Report View ACRX OTC Short Report - OTCShortReport.com
TradeKing View ACRX Fundamentals - TradeKing Charts View ACRX SEC Filings - Bar Chart
WSJ View Historical Prices for ACRX - The WSJ Morningstar View Performance/Total Return for ACRX - Morningstar
MarketWatch View the Analyst Estimates for ACRX - MarketWatch CNBC View the Earnings History for ACRX - CNBC
StockMarketWatch View the ACRX Earnings - StockMarketWatch MacroAxis View ACRX Buy or Sell Recommendations - MacroAxis
Bullish View the ACRX Bullish Patterns - American Bulls Short Pains View ACRX Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ACRX Stock Mentions - StockTwits PennyStocks View ACRX Stock Mentions - PennyStockTweets
Twitter View ACRX Stock Mentions - Twitter Invest Hub View ACRX Investment Forum News - Investor Hub
Yahoo View ACRX Stock Mentions - Yahoo! Message Board Seeking Alpha View ACRX Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for ACRX - SECform4.com Insider Cow View Insider Transactions for ACRX - Insider Cow
CNBC View ACRX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ACRX - OTC Markets
Yahoo View Insider Transactions for ACRX - Yahoo! Finance NASDAQ View Institutional Holdings for ACRX - NASDAQ


Stock Charts

FinViz View ACRX Stock Insight & Charts - FinViz.com StockCharts View ACRX Investment Charts - StockCharts.com
BarChart View ACRX Stock Overview & Charts - BarChart Trading View View ACRX User Generated Charts - Trading View


Latest Financial News for ACRX

Omeros Inks Agreement With FDA for OMS721 Phase III Trial
Posted on Thursday January 04, 2018

Omeros (OMER) inks an agreement with the FDA on Omeros' protocol for a phase III study to evaluate its lead pipeline candidate, OMS721, for treatment of patients with IgA nephropathy.


Merck's Keytruda Gets Approved for Bladder Cancer in Japan
Posted on Wednesday January 03, 2018

Merck's (MRK) anti-PD-1 therapy, Keytruda, gains approval in Japan for previously-treated patients with bladder cancer. Keytruda can now be indicated for four types of cancer in Japan.


AcelRx Pharmaceuticals Inc’s (NASDAQ:ACRX) Earnings Declined -16.55%, But How Did It Fare Against The Industry?
Posted on Wednesday January 03, 2018

Examining AcelRx Pharmaceuticals Inc’s (NASDAQ:ACRX) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has met orRead More...


AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q3, 2017 By the Numbers : January 3, 2018
Posted on Wednesday January 03, 2018

Categories: Yahoo FinanceGet free summary analysis AcelRx Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. Highlights Summary numbers: Revenues of USD 1.49 million, Net Earnings of USD -13.01 million. Gross margins narrowed from 23.38% to -36.45% compared to the same period last year, operating (EBITDA) margins now -566.31% from -221.60%. Change in operating ... Read more (Read more...)


AcelRx Pharmaceuticals Inc. (ACRX) Moves Lower on Volume Spike for December 28
Equities.com - Dec 28, 2017
AcelRx Pharmaceuticals Inc. (ACRX) traded on unusually high volume on Dec. 28, as the stock lost 2.5% to close at $1.95. On the day, AcelRx Pharmaceuticals Inc. saw 932,373 shares trade hands on 1,581 trades. Considering that the stock averages only a ...
Hot Stock of the Day: AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) - Alpha Beta Stock
At This Price, Is It Too Late To Buy AcelRx Pharmaceuticals, Inc. (ACRX)? - AllStockNews

AcelRx Pharmaceuticals Inc. (ACRX) Soars 6.1% on January 05
Equities.com - Jan 5, 2018
AcelRx Pharmaceuticals Inc. (ACRX) had a good day on the market for Friday January 05 as shares jumped 6.1% to close at $2.18.

AcelRx Stock Looks Weak Ahead Of Revised NDA Submissions For 2 Products
Seeking Alpha - Dec 29, 2017
AcelRx Pharmaceuticals, Inc. (ACRX) stock lost all its gains made till October after it posted a steep decline that month.

AcelRx Pharmaceuticals (ACRX) Rating Increased to Buy at Zacks Investment Research
The Ledger Gazette - Jan 20, 2018
AcelRx Pharmaceuticals (NASDAQ:ACRX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday, December 27th.
AcelRx Pharmaceuticals (ACRX) Stock Rating Upgraded by Zacks Investment Research - Dispatch Tribunal
AcelRx Pharmaceuticals (ACRX) Stock Rating Lowered by Zacks Investment Research - StockNewsTimes

Enter a stock symbol to view the stock details.